This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

This joint resolution nullifies the Environmental Protection Agency rule titled Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA) (89 Fed. Reg. 102568) and published on December 17, 2024. Among other elements, the rule prohibits the manufacturing, import, processing, and distribution in commerce of trichloroethylene (TCE) for all uses (including consumer uses), and prohibits the industrial and commercial use of TCE.

No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025

Main Street Tax Certainty Act

No Abortion Coverage for Medicaid ActThis bill prohibits the Centers for Medicare & Medicaid Services from approving experimental, pilot, or demonstration projects under Medicaid (also known as Section 1115 Demonstrations) if the project provides federal financial assistance for abortions or for health benefits that include abortions, including expenses for related travel or lodging.The bill's restrictions do not apply to abortions in the cases of rape or incest; treatments to address life-threatening physical disorders, injuries, or illnesses; or treatments for miscarriages or ectopic pregnancies.

Protecting Life in Health Savings Accounts ActThis bill excludes expenses paid for an abortion from qualified medical expenses eligible for reimbursement from certain tax-exempt savings accounts. (Some exceptions apply.)Under the bill, amounts paid for an abortion, other than an excluded abortion, are not qualified medical expenses eligible for reimbursement from a health savings account, Archer medical savings account, health flexible spending arrangement, health reimbursement arrangement, or retiree health account.The bill defines excluded abortion as any abortion (1) related to a pregnancy that is the result of rape or incest; or (2) performed because a woman is suffering from a physical disorder, injury, or illness (including a life-endangering physical condition caused by or arising from the pregnancy itself) that would, as certified by a physician, place the woman in danger of death if an abortion were not performed.

Life at Conception Act

Medicare Patient Access and Practice Stabilization Act of 2025

Dismantle DEI Act of 2025

Saving Seniors Money on Prescriptions ActThis bill establishes reporting requirements for pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs.Specifically, PBMs must (1) disclose certain information underlying cost performance measurements (e.g., exclusions and terms), and (2) report to prescription drug plan (PDP) sponsors (and to the Centers for Medicare & Medicaid Services upon request) an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with this bill's requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations.In addition, the Government Accountability Office must study federal and state reporting requirements for health plans and PBMs with respect to prescription drug price transparency and recommend ways to streamline these requirements.

Fair Access to Banking Act

Expressing the sense of Congress that the United States should resume normal diplomatic relations with Taiwan, negotiate a bilateral free trade agreement with Taiwan, and support Taiwans membership in international organizations.

Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the United States Fish and Wildlife Service relating to "Barred Owl Management Strategy".

Proposing an amendment to the Constitution of the United States to limit the number of terms that a Member of Congress may serve.

Proposing an amendment to the Constitution of the United States to require that the Supreme Court of the United States be composed of nine justices.